Caris Life Sciences (CAI) News
NASDAQ: CAIHealth CareMedical SpecialitiesUSD
17.58-0.96 (-5.18%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CAI news summary
We found 48 recent headlines mentioning Caris Life Sciences (CAI): 1 in the past week and 13 in the past 30 days, most often from Nasdaq, Seeking Alpha, PR Newswire. CAI is making an outsized move today, down 5.18% at $17.58, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Why is Caris Life Sciences stock rallying today?", was published by Investing.com on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Caris Life Sciences headlines
- Why is Caris Life Sciences stock rallying today?Investing.com
- BTSG vs. CAI: Which Stock Should Value Investors Buy Now?BTSG vs. CAI: Which Stock Is the Better Value Option?NasdaqBTSG, CAI
- Caris Life (CAI) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaqCAI, WSO.B
- Caris Q3 Net Income Declines 37% Despite 27% Revenue Growth; Raises FY26 Outlook(RTTNews) - Caris Life Sciences, Inc. (CAI), a TechBio company focused on precision medicine and molecular profiling, reported lower third-quarter 2026 net income as operating expenses increased,…NasdaqCAI, HEI.A
- Caris Q3 Profit Falls On Higher Expenses; Raises FY26 Revenue Guidance After 27% Revenue Growth(RTTNews) - Caris Life Sciences, Inc. (CAI) reported a decline in third-quarter net income as expenses increased. The TechBio company posted 27% revenue growth for the quarter and raised its…NasdaqCAI, BRK.A
- Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call TranscriptSeeking Alpha
- Caris Life Sciences,?Inc. (CAI) Q3 Earnings and Revenues Top EstimatesCaris Life Sciences,?Inc. (CAI) delivered earnings and revenue surprises of +66.67% and +9.75%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for…NasdaqCAI, NTRA
- Caris Life Sciences, Inc. GAAP EPS of $0.05 beats by $0.02, revenue of $275.4M beats by $20.06MSeeking Alpha
- Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue GuidanceRevenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests Raises 2026 revenue…PR Newswire
- Caris Life Sciences Q3 26 Earnings Conference Call At 4:30 PM ET(RTTNews) - Caris Life Sciences, Inc. (CAI) will host a conference call at 4:30 PM ET on November 4, 2026 to discuss Q3 26 earnings results.Nasdaq
- Caris Life Sciences, Inc. Q3 2026 Earnings PreviewSeeking Alpha
- Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.NasdaqVTRS, CAI
- Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out forCaris Life Sciences,?Inc. (CAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Nasdaq
- Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer DetectionNew campaign connects AI-powered performance insights linking advanced molecular intelligence to help detect cancer in earlier stages IRVING, Texas, Oct. 19, 2026 /PRNewswire/ -- Caris Life Sciences®…PR Newswire
- Caris Life Sciences: Adjusting My Position After A Recent Steep Incline (Downgrade)Seeking Alpha
- Are Medical Stocks Lagging Bristol Myers Squibb (BMY) This Year?Here is how Bristol Myers Squibb (BMY) and Caris Life Sciences,?Inc. (CAI) have performed compared to their sector so far this year.NasdaqBMY, CAI
- Caris Life Sciences: Diagnostics Growth With Room To RunSeeking Alpha
- Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.NasdaqRVTY, CAI
- Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?Caris Life Sciences, Inc. (CAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in…NasdaqCAI, INNV
- Caris Life Sciences, Inc. 2026 Q2 - Results - Earnings Call PresentationSeeking Alpha
- Caris Life Sciences: Guidance Raised, Valuation Still AttractiveSeeking Alpha
- Caris forecasts $1.03B-$1.04B 2026 revenue as it scales Detect capacity toward $3B run rateSeeking Alpha
- Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call TranscriptSeeking Alpha
- Caris Life Sciences Q2 Earnings Call HighlightsCaris Life Sciences (NASDAQ:CAI) reported record clinical volume and raised its full-year revenue outlook after second-quarter revenue increased 45% from a year earlier, driven by growth in molecular…Nasdaq
- Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2Caris Life Sciences,?Inc. (CAI) delivered earnings and revenue surprises of +100.00% and +14.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the…NasdaqCAI, CYRX
- CareDx (CDNA) Beats Q2 Earnings and Revenue EstimatesCareDx (CDNA) delivered earnings and revenue surprises of +68.18% and +15.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqCDNA, CAI
- Caris Life Sciences: Disrupting Cancer Screening And Therapy SelectionSeeking Alpha
- Caris Life Sciences: The Discount To Peers Looks Hard To IgnoreSeeking Alpha
- Caris Life Sciences, Inc. (CAI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking AlphaCAI, GS
- Caris Life Sciences Authorized Buy Back Up To $100 Mln(RTTNews) - Caris Life Sciences (CAI), an AI TechBio company, Monday announced that it has been authorized to repurchase up to $100 million of the company's outstanding common stock.Nasdaq
- Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%Caris Life Sciences (NASDAQ:CAI) executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following its…Nasdaq
- Caris Life Sciences, Inc. (CAI) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking AlphaCAI, BAC
- Caris Life Sciences, Inc. (CAI) Q1 2026 Earnings Call TranscriptSeeking Alpha
- Caris (CAI) Q1 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Caris Life Sciences Q1 Loss Narrows(RTTNews) - Caris Life Sciences (CAI) on Thursday reported first-quarter results with revenue rising sharply from last year while losses narrowed, driven by strong growth in molecular profiling…Nasdaq
- Caris Life Sciences Q1 Earnings Call HighlightsCaris Life Sciences (NASDAQ:CAI) reported first-quarter 2026 results highlighted by sharp year-over-year revenue growth, improving margins, and continued progress across its pipeline, including a key…Nasdaq
- Caris Life Sciences, Inc. 2026 Q1 - Results - Earnings Call PresentationSeeking Alpha
- Caris Develops Predictive AI Model For Selection Of Glioblastoma Therapies(RTTNews) - Caris Life Sciences (CAI), an artificial intelligence TechBio and precision medicine company, announced on Wednesday the development and peer-reviewed publication of a predictive…Nasdaq
- Jefferies Initiates Coverage of Caris Life Sciences (CAI) with Buy RecommendationFintel reports that on April 13, 2026, Jefferies initiated coverage of Caris Life Sciences (NasdaqGS:CAI) with a Buy recommendation. Analyst Price Forecast Suggests 71.99% UpsideNasdaq
- Caris Life Sciences: Post-IPO Pullback Creates A Long-Term Buy OpportunitySeeking Alpha
- Piper Sandler Initiates Coverage of Caris Life Sciences (CAI) with Neutral RecommendationFintel reports that on April 10, 2026, Piper Sandler initiated coverage of Caris Life Sciences (NasdaqGS:CAI) with a Neutral recommendation. Analyst Price Forecast Suggests 82.32% UpsideNasdaq
- Caris Life Sciences Launches AI-Powered Molecular Insight To Guide Chemotherapy Decision In NSCLC(RTTNews) - Caris Life Sciences (CAI) has introduced a new multimodal, AI-driven molecular insight designed to help determine whether certain non-small cell lung cancer patients benefit from adding…Nasdaq
- Caris Life Sciences, Inc. (CAI) Q4 2025 Earnings Call TranscriptSeeking Alpha
- Caris Life Sciences, Inc. (CAI) Presents at 44th Annual J.P. Morgan Healthcare Conference - SlideshowSeeking Alpha
- Caris Life Sciences, Inc. (CAI) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha
- Caris Life Sciences: Stronger Fundamentals, Same ConclusionSeeking Alpha
- Caris Life Sciences, Inc. (CAI) Q3 2025 Earnings Call TranscriptSeeking Alpha
- Caris Life Sciences, Inc. 2025 Q3 - Results - Earnings Call PresentationSeeking Alpha